Recorded fact · drug.label_indication
drug.label_indication for axitinib|renal-cell-carcinoma
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 09f53e60 resolves to.
The record
| Fact id | 09f53e6003cb9b3ea3324b07 |
|---|---|
| Entity | drug: axitinib|renal-cell-carcinoma |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20250219 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 9ef99fe8596b70549df92dd08adb0d7130de4f8101158c4a8f98ad082faf9648.
The value
{
"ingredient": "Axitinib",
"conditionId": "renal-cell-carcinoma",
"conditionName": "Renal Cell Carcinoma",
"matchedAlias": "renal cell carcinoma",
"context": "indication",
"brand": "INLYTA",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "84137882-e000-47da-bd5b-fa76ab3c76f9",
"labelEffectiveTime": "20250219",
"labelsRead": 2,
"labelsNaming": 2,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: ac6d5c876c8598a72b6947aaa37818f4fe6b447c91ac6aff8ffdf4611eabc440.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.